APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Duchenne Muscular Dystrophy (DMD) Therapeutics

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

Selected research

Market Structure

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173894070327 December 2025187 pages

Choose your research edition.

Industry ResearchDuchenne Muscular Dystrophy (DMD) Therapeutics Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

By region, North America has the highest market share, reaching 70.66% in 2019.

Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.

Read the full market overview

Report Includes

This report provides an overview of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Duchenne Muscular Dystrophy (DMD) Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Duchenne Muscular Dystrophy (DMD) Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Duchenne Muscular Dystrophy (DMD) Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Company

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Type

Exondys

Emflaza

Translarna

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Application

Hospitals

Clinics

Home Care

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Duchenne Muscular Dystrophy (DMD) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duchenne Muscular Dystrophy (DMD) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Duchenne Muscular Dystrophy (DMD) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Duchenne Muscular Dystrophy (DMD) Therapeutics industry.

Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Duchenne Muscular Dystrophy (DMD) Therapeuticsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Exondys Table 3. Key Players of Emflaza Table 4. Key Players of Translarna Table 4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hospitals Table 6. Key Players of Clinics Table 7. Key Players of Home Care Table 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2021-2026) Table 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2027-2032) Table 13. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends Table 14. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Drivers Table 15. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Opportunities and Challenges Table 16. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Restraints Table 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Company (2021-2026) Table 19. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Key Company Head Office and Area Served Table 21. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company, Product Type & Application Table 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2021-2026) Table 29. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2027-2032) Table 30. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2021-2026) Table 34. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2027-2032) Table 35. Sarepta Therapeutics Company Information Table 36. Sarepta Therapeutics Business Overview Table 37. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 39. Sarepta Therapeutics Recent Development Table 40. PTC Therapeutics Company Information Table 41. PTC Therapeutics Business Overview Table 42. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 44. PTC Therapeutics Recent Development Table 45. Pfizer Company Information Table 46. Pfizer Business Overview Table 47. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 49. Pfizer Recent Development Table 50. Bristol-Myers Squibb Company Information Table 51. Bristol-Myers Squibb Business Overview Table 52. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 54. Bristol-Myers Squibb Recent Development Table 55. Italfarmaco Company Information Table 56. Italfarmaco Business Overview Table 57. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 59. Italfarmaco Recent Development Table 60. Santhera Pharmaceuticals Company Information Table 61. Santhera Pharmaceuticals Business Overview Table 62. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 64. Santhera Pharmaceuticals Recent Development Table 65. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 66. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 67. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 68. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 69. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 70. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026) Table 71. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027-2032) Table 72. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 73. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 74. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 75. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 76. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 77. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026) Table 78. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027-2032) Table 79. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 80. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 81. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 82. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 83. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 84. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 85. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 86. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 87. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026) Table 89. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027-2032) Table 90. South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 91. South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2027-2032) & (US$ Million) Table 92. South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 93. South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2027-2032) & (US$ Million) Table 94. South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026) Table 96. South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027-2032) Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Product Image Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type: 2025 VS 2032 Figure 4. Exondys Image Figure 5. Emflaza Image Figure 6. Translarna Image Figure 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application: 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Home Care Image Figure 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players in 2025 Figure 17. Global Top 5 and 10 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2021-2032) Figure 21. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2021-2032) Figure 23. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 24. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2021-2032) Figure 25. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2021-2032) Figure 26. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2032) Figure 27. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 28. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 29. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 30. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 31. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2021-2032) Figure 32. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2021-2032) Figure 33. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2032) Figure 34. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 35. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 36. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 37. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 38. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 40. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 41. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2021-2032) Figure 42. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2021-2032) Figure 43. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 44. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2021-2032) Figure 45. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2021-2032) Figure 46. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2032) Figure 47. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 48. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 51. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 52. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2032) Figure 57. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 58. South Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 60. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 61. Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 62. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 63. Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 64. Chile Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • Exondys
  • Emflaza
  • Translarna
Applications
  • Hospitals
  • Clinics
  • Home Care
Companies covered
  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Exondys
  5. 1.2.3 Emflaza
  6. 1.2.4 Translarna
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.3.4 Home Care
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trends by Region
  14. 1.5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2021-2026)
  16. 1.5.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
  1. 2.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
  2. 2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Drivers
  3. 2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Company (2021-2026)
  2. 3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Key Company Head office and Area Served
  4. 3.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company, Product Type & Application
  5. 3.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Duchenne Muscular Dystrophy (DMD) Therapeutics Tier 1, Tier 2, and Tier 3
4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type
  1. 4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021-2032)
  3. 4.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Type (2021-2032)
5 Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Application
  1. 5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021-2032)
  3. 5.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Sarepta Therapeutics
  2. 6.1.1 Sarepta Therapeutics Company Information
  3. 6.1.2 Sarepta Therapeutics Business Overview
  4. 6.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  6. 6.1.5 Sarepta Therapeutics Recent Developments
  7. 6.2 PTC Therapeutics
  8. 6.2.1 PTC Therapeutics Company Information
  9. 6.2.2 PTC Therapeutics Business Overview
  10. 6.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  12. 6.2.5 PTC Therapeutics Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 Bristol-Myers Squibb
  20. 6.4.1 Bristol-Myers Squibb Company Information
  21. 6.4.2 Bristol-Myers Squibb Business Overview
  22. 6.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  24. 6.4.5 Bristol-Myers Squibb Recent Developments
  25. 6.5 Italfarmaco
  26. 6.5.1 Italfarmaco Company Information
  27. 6.5.2 Italfarmaco Business Overview
  28. 6.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  30. 6.5.5 Italfarmaco Recent Developments
  31. 6.6 Santhera Pharmaceuticals
  32. 6.6.1 Santhera Pharmaceuticals Company Information
  33. 6.6.2 Santhera Pharmaceuticals Business Overview
  34. 6.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  36. 6.6.5 Santhera Pharmaceuticals Recent Developments
7 North America
  1. 7.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032)
  2. 7.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
  3. 7.2.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021-2026)
  4. 7.2.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2027-2032)
  5. 7.2.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2021-2032)
  6. 7.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
  7. 7.3.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021-2026)
  8. 7.3.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2027-2032)
  9. 7.3.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2021-2032)
  10. 7.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
  11. 7.4.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026)
  13. 7.4.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027-2032)
  14. 7.4.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032)
  2. 8.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
  3. 8.2.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021-2026)
  4. 8.2.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2027-2032)
  5. 8.2.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2021-2032)
  6. 8.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
  7. 8.3.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021-2026)
  8. 8.3.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2027-2032)
  9. 8.3.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2021-2032)
  10. 8.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
  11. 8.4.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026)
  13. 8.4.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027-2032)
  14. 8.4.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032)
  2. 9.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
  3. 9.2.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021-2026)
  4. 9.2.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2027-2032)
  5. 9.2.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2021-2032)
  6. 9.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
  7. 9.3.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021-2026)
  8. 9.3.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2027-2032)
  9. 9.3.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032)
  2. 10.2 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
  3. 10.2.1 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021-2026)
  4. 10.2.2 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2027-2032)
  5. 10.2.3 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2021-2032)
  6. 10.3 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
  7. 10.3.1 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021-2026)
  8. 10.3.2 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2027-2032)
  9. 10.3.3 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2021-2032)
  10. 10.4 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
  11. 10.4.1 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026)
  13. 10.4.3 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027-2032)
  14. 10.4.4 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst